V
VIRIDIAN THERAPEUTICS INC
NASDAQ: VRDN (Viridian Therapeutics, Inc.)
最近更新时间: 14小时之前22.00
0.07 (0.32%)
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | Viridian Therapeutics, Inc. | 混合的 | 看涨 |
AIStockmoo 评分
1.3
| 分析师共识 | NA |
| 内部交易活动 | NA |
| 价格波动 | 2.0 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | -0.5 |
| 平均 | 1.33 |
|
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED). |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Core |
| 内部持股比例 | 0.16% |
| 机构持股比例 | 114.61% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Bellevue Group Ag | 30 Jun 2026 | 6,731,909 |
| Paradigm Biocapital Advisors Lp | 30 Jun 2026 | 6,723,788 |
| Kynam Capital Management, Lp | 30 Jun 2026 | 6,453,877 |
| Fairmount Funds Management Llc | 30 Jun 2026 | 5,090,928 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合